NovaLaka

Company Overview

Snapshot

Founded in October 2015 by Eva Smagacz, NovaLaka operates with 1–10 employees. The company has secured $57,000 across one funding round from one investor. In May 2017, NovaLaka received funding from the Israel Innovation Authority.

Business overview

NovaLaka develops slow-release transmucosal drug delivery systems, primarily focusing on women's healthcare applications. The company's core technology involves a polymeric composition that serves as a drug-delivery system for mucosal tissues, such as the eyes. This polymeric matrix gradually releases medication directly to the treatment area, functioning as a vehicle for various active ingredients to be delivered effectively and in a controlled manner. NovaLaka operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, targeting areas like drug discovery and development.

Strategic signal

In June 2017, NovaLaka won first prize at the Global Pitch of China, signaling early international recognition and validation for its innovative drug delivery technology. This achievement highlights the company's potential to attract global partners and expand its market reach, demonstrating a strong competitive edge in the pharmaceutical and health tech landscape.

Company Intelligence Q&A

What is NovaLaka's primary focus in drug delivery?

NovaLaka specializes in slow-release transmucosal drug delivery systems, particularly for women's healthcare applications, utilizing a polymeric composition to deliver medication directly to mucosal tissues.

When was NovaLaka founded and by whom?

NovaLaka was founded in October 2015 by Eva Smagacz.

What was a significant early achievement for NovaLaka?

In June 2017, NovaLaka won the first prize at the Global Pitch of China, an international startup competition.

What is NovaLaka's current operational status?

NovaLaka ceased to operate in December 2019.